Oshrat Frenkel

Oshrat Frenkel, hailing from Modiin, Israel, is an accomplished inventor known for her significant contributions to the field of pharmaceutical sciences. With a keen expertise in solid-state chemistry and drug formulation, Frenkel has become a notable figure in the realm of patented innovations.

Latest Patents

Frenkel holds a patent for the "Crystalline form E1 of larotrectinib ethanesulfonate." This patent encompasses salts and solid-state forms of larotrectinib, highlighting processes for their preparation, pharmaceutical compositions, and their various uses. This innovative work is crucial in the development of effective treatments for certain types of cancer, showcasing Frenkel's dedication to advancing medical science.

Career Highlights

Currently, Oshrat Frenkel is associated with Assia Chemical Industries Ltd., where she plays a pivotal role in research and development. Her work focuses on the synthesis and characterization of novel pharmaceutical compounds, contributing to the company’s commitment to innovation in the pharmaceutical industry.

Collaborations

Throughout her career, Frenkel has collaborated with esteemed colleagues, including Sharona Shachan-Tov and Doron Rudik. These partnerships have fostered an environment of creativity and innovation, allowing for the sharing of ideas and expertise that drive their projects forward.

Conclusion

Oshrat Frenkel exemplifies the spirit of innovation with her cutting-edge patents and collaborative efforts in the pharmaceutical landscape. Her contributions continue to pave the way for advancements that have the potential to significantly impact healthcare and improve patient outcomes.

Profile summary based on public USPTO records.